Kennedy Makes Unfounded Claim That Keto Diet Can ‘Cure’ Schizophrenia – The New York Times

Lead

On Feb. 5, 2026, Health Secretary Robert F. Kennedy Jr., speaking in Nashville at the Tennessee State Capitol, asserted that the ketogenic (keto) diet can cure schizophrenia. His remarks accompanied a public tour promoting an overhaul of federal dietary guidance that favors proteins and fats over carbohydrates. Medical researchers and psychiatric experts say Kennedy’s statement overreaches current evidence, which is limited to small case reports and preliminary investigations. The claim has prompted immediate scrutiny from clinicians and advocates concerned about misleading public health messages.

Key Takeaways

• Robert F. Kennedy Jr. made the claim on Feb. 5, 2026, in Nashville while promoting new federal dietary guidance favoring fats and proteins.
• Kennedy cited work by Dr. Christopher Palmer at Harvard, referencing a 2019 report of two patients with schizophrenia who reportedly experienced remission on a keto diet.
• Experts say the evidence for keto as a schizophrenia cure is currently limited to isolated case reports and early-stage studies, not large randomized trials.
• Kennedy also claimed that diet changes led some people to lose a bipolar diagnosis, a statement experts say is not supported by robust published data.
• Public health advocates warn that overstating early research can encourage patients to stop evidence-based psychiatric treatment without medical supervision.
• The exchange has raised questions about how federal dietary messaging intersects with mental health policy and clinical care.

Background

The ketogenic diet is a high-fat, low-carbohydrate eating pattern that has been studied for decades in contexts such as epilepsy and weight management. Interest in keto’s effects on brain function has grown recently, with researchers exploring metabolic pathways that might influence psychiatric conditions. In 2019, Dr. Christopher Palmer described two longstanding schizophrenia patients who reportedly entered remission while following a ketogenic regimen; that report was a case-based observation rather than a controlled trial. Since then, clinicians and investigators have called for carefully designed studies to test whether metabolic interventions can produce reproducible clinical benefits in psychosis or mood disorders.

Robert F. Kennedy Jr. has been publicly promoting changes to federal dietary guidance that emphasize meats, dairy fats and proteins over carbohydrates. His national tour urging Americans to “eat real food” links broader nutrition policy to mental health claims, a pairing that specialists say requires rigorous evidence. Psychiatric treatment for schizophrenia typically relies on antipsychotic medications, psychosocial interventions and long-term follow-up—standards derived from extensive clinical trials. Shifting public perception about treatment based on preliminary dietary reports risks disrupting established care pathways if messages are not carefully qualified.

Main Event

During his Tennessee appearance, Kennedy told the crowd that food choices are driving mental illness in the United States and specifically credited a Harvard physician with curing schizophrenia via keto. He stated that he had recently seen studies suggesting dramatic diagnostic changes, including reports of people losing a bipolar diagnosis after changing diet. Those assertions closely echo a public narrative that positions diet as a direct causal and curative factor for serious psychiatric disorders.

Kennedy’s reference appears to track to Dr. Christopher Palmer’s 2019 description of two patients who experienced prolonged remission while following a ketogenic diet and who reportedly discontinued antipsychotic medications. Dr. Palmer and colleagues later characterized the diet as a “promising therapeutic approach for schizophrenia,” language that signals cautious optimism rather than definitive proof. The distinction between a preliminary, hypothesis-generating observation and an established clinical treatment is central to the debate triggered by Kennedy’s remarks.

Medical experts who spoke to journalists after the appearance emphasized that isolated case reports cannot determine causal efficacy for a heterogeneous disorder like schizophrenia. They noted that remission in individual patients can reflect many factors, including natural course, concurrent treatments, placebo effects, or other lifestyle changes. Clinicians also warned against patients stopping antipsychotic medication without physician guidance—doing so can carry substantial risks of relapse and harm.

Analysis & Implications

Kennedy’s public statement amplifies a complex scientific question into a simple, actionable claim—one likely to be picked up by social and traditional media. When high-profile figures present preliminary findings as settled fact, the public may overestimate the strength of evidence and make medical decisions without adequate consultation. For schizophrenia, where treatment adherence and monitoring are critical, miscommunication can have direct patient safety consequences.

From a policy perspective, the episode highlights tensions between nutrition guidance and mental health policy. Federal dietary recommendations reach millions and can influence food procurement, school meals and public messaging. Conflating exploratory clinical observations with guidance suitable for population-level policy can lead to premature changes in programs or expectations. Policymakers should weigh the quality and reproducibility of evidence before linking national guidelines to psychiatric outcomes.

Scientifically, interest in metabolic interventions for psychiatric disorders is legitimate and growing. Researchers are investigating mechanisms—such as altered energy metabolism, inflammation and gut-brain interactions—that could plausibly affect mood and cognition. However, establishing a causal, generalizable treatment requires randomized controlled trials, replication across diverse patient groups, and careful measurement of harms and benefits. Until those conditions are met, describing keto as a “cure” overstates the current state of knowledge.

Comparison & Data

The available public record identifies Dr. Palmer’s 2019 report as a case-based observation and later commentary describing the approach as promising. That pattern—initial case observations followed by small exploratory work—is common in early-stage clinical research. It illustrates why clinicians and guideline developers require progressively more rigorous evidence before changing standard care recommendations.

Reactions & Quotes

“We now know that the things that you eat are driving mental illness in this country.”

Robert F. Kennedy Jr., Health Secretary (speech, Feb. 5, 2026)

“Two patients with longstanding schizophrenia experienced complete remission of symptoms on a ketogenic diet,”

Dr. Christopher Palmer (2019 case report)

Experts caution that these early reports do not establish that ketogenic diets cure schizophrenia and warn against changing medications without medical oversight.

Psychiatric clinicians and researchers (paraphrased)

Unconfirmed

• That the ketogenic diet is a reliable or generalizable cure for schizophrenia—current evidence is limited and not definitive.
• That changing diet alone routinely leads to loss of a bipolar disorder diagnosis—such claims lack support from large, controlled studies.

Bottom Line

Robert F. Kennedy Jr.’s statement that the keto diet can cure schizophrenia amplifies a promising but preliminary line of inquiry into a definitive public-health claim. The underlying reports—primarily case observations—are insufficient to support a recommendation that patients discontinue standard psychiatric treatments. Clinicians and health agencies should emphasize that dietary interventions under study must be evaluated in rigorous trials before being presented to the public as curative.

For patients and caregivers, the appropriate takeaway is cautious interest rather than action: discuss any contemplated dietary changes with treating clinicians, particularly before altering or stopping antipsychotic medication. For policymakers, the episode underscores the need for careful translation of early scientific findings into public guidance and for clearly distinguishing exploratory research from established medical practice.

Sources

• The New York Times (news report summarizing the Feb. 5, 2026 remarks and relevant research)
• PubMed search for Christopher Palmer 2019 case report (academic sources and case description)